Hariprasad Vankayalapati (Hariprasad Vankayalapat)

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 3

Top Topics

Breast Cancer Risk

Clinical Evaluation

Tyrosine Kinase

Endoplasmic Reticulum

Top Venues

Cancer research

BioMed research international

This page only lists publications with an associated author ORCID identifier.

Publications

Anudishi Tyagi, Appalaraju Jaggupilli, Stanley Ly, Bin Yuan, Fouad El-Dana, Venkatesh L Hegde, Vivek Anand, Bijender Kumar, Mamta Puppala, Zheng Yin, Stephen T C Wong, Alexis Mollard, Hariprasad Vankayalapati, Jason M Foulks, Steven L Warner, Naval G Daver, Gautam Borthakur, Venkata Lokesh Battula
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia (2023)
Kristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu, Junhao Liu, Uday P Pratap, Behnam Ebrahimi, John R Sanchez, Xiaonan Li, Shihong Ma, Ben Ho Park, Bindu Santhamma, Yidong Chen, Zhao Lai, Ganesh V Raj, Yaxia Yuan, Daohong Zhou, Gangadhara R Sareddy, Rajeshwar R Tekmal, Stanton F McHardy, Tim Hui-Ming Huang, Manjeet K Rao, Hariprasad Vankayalapati, Ratna K Vadlamudi
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer. Cancer research 82 (20) (2022)
Dengxuan Fan, Hailing Yang, Weiqun Mao, Philip J Rask, Lan Pang, Congjian Xu, Hariprasad Vankayalapati, Ahmed A Ahmed, Robert C Bast, Zhen Lu
A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers 13 (3) (2021)
Lingyao Meng, Kent Carpenter, Alexis Mollard, Hariprasad Vankayalapati, Steven L Warner, Sunil Sharma, Guido Tricot, Fenghuang Zhan, David J Bearss
Inhibition of Nek2 by small molecules affects proteasome activity. BioMed research international 2014 (2014)